Leveraging contact network structure in the design of cluster randomized trials

Clinical Trials

Volumn 14, Issue 1, 2017, Pages 37-47

  Harling, Guy ^a   Wang, Rui ^a,b   Onnela, Jukka Pekka ^a   De Gruttola, Victor ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

cluster randomized trial; Ebola; epidemic control; network; power; Vaccine

Indexed keywords

ARTICLE; COMPARATIVE EFFECTIVENESS; CONTACT NETWORK STRUCTURE; DISEASE CONTROL; EBOLA HEMORRHAGIC FEVER; EPIDEMIC CONTROL; FUZZY ORDER DESIGN; INCIDENCE; INFORMATION PROCESSING; INTERMETHOD COMPARISON; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIMULATION; SOCIAL NETWORK; STANDARD STEPPED WEDGE DESIGN; STUDY DESIGN; THERAPY EFFECT; VACCINATION; COMPUTER SIMULATION; EPIDEMIC; HUMAN; METHODOLOGY; PUBLIC HEALTH; TIME FACTOR;

EBOLA VACCINE;

COMPUTER SIMULATION; DISEASE OUTBREAKS; EBOLA VACCINES; HEMORRHAGIC FEVER, EBOLA; HUMANS; PUBLIC HEALTH; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; TIME FACTORS;

EID: 85012077035     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774516673355     Document Type: Article

References (32)

1. Halloran ME, Struchiner CJ, Longini IM., Study designs for evaluating different efficacy and effectiveness aspects of vaccines. Am J Epidemiol 1997; 146: 789-803
2. Halloran ME, Struchiner CJ., Study designs for dependent happenings. Epidemiology 1991; 2: 331-338
3. Halloran ME, Haber M, Longini IM, et al. Direct and indirect effects in vaccine efficacy and effectiveness. Am J Epidemiol 1991; 133: 323-331
4. Hussey MA, Hughes JP., Design and analysis of stepped wedge cluster randomized trials. Contemp Clin Trials 2007; 28: 182-191
5. Lipsitch M, Eyal N, Halloran ME, et al. Ebola and beyond. Science 2015; 348: 46-48
6. Hargreaves JR, Prost A, Fielding KL, et al. How important is randomisation in a stepped wedge trial? Trials 2015; 16: 359
7. Campbell M, Donner A, Klar N., Developments in cluster randomized trials and statistics in medicine. Stat Med 2007; 26: 2-19
8. Hayes R, Alexander ND, Bennett S, et al. Design and analysis issues in cluster-randomized trials of interventions against infectious diseases. Stat Methods Med Res 2000; 9: 95-116
9. Hayes R, Moulton L., Cluster randomised trials. Boca Raton, FL: Chapman & Hall/CRC, 2009
10. Wang R, Goyal R, Lei Q, et al. Sample size considerations in the design of cluster randomized trials of combination HIV prevention. Clin Trials 2014; 11: 309-318
11. Bellan SE, Pulliam JR, Pearson CA, et al. Statistical power and validity of Ebola vaccine trials in Sierra Leone: a simulation study of trial design and analysis. Lancet Infect Dis 2015; 15: 703-710
12. Hébert-Dufresne L, Allard A, Young JG, et al. Global efficiency of local immunization on complex networks. Sci Rep 2013; 3: 2171
13. Meyers L., Contact network epidemiology: bond percolation applied to infectious disease prediction and control. Bull Am Math Soc 2007; 44: 63-86
14. Cohen R, Havlin S, Ben-Avraham D., Efficient immunization strategies for computer networks and populations. Phys Rev Lett 2003; 91: 247901
15. Keeling M, Woolhouse M, May R, et al. Modelling vaccination strategies against foot-and-mouth disease. Nature 2003; 421: 136-142
16. Kretzschmar M, Van den Hof S, Wallinga J, et al. Ring vaccination and smallpox control. Emerg Infect Dis 2004; 10: 832-841
17. Enserink M., High hopes for Guinean vaccine trial. Science 2015; 347: 219-220
18. Ebola ça Suffit Ring Vaccination Trial Consortium. The ring vaccination trial: a novel cluster randomized controlled trial design to evaluate vaccine efficacy and effectiveness during outbreaks, with special reference to Ebola. BMJ 2015; 351: h3740
19. World Health Organization. Questions and answers-Ebola phase III vaccine trial in Guinea. Geneva: World Health Organization, 2015
20. Henao-Restrepo AM, Longini IM, Egger M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet 2015; 386: 857-866
21. Anderson CJ, Wasserman S, Faust K., Building stochastic blockmodels. Soc Networks 1992; 14: 137-161
22. Check Hayden E,. Disease specialists identify post-Ebola threats. Nature. Epub ahead of print 7 December 2015. DOI: 10.1038/nature.2015.18952
23. Legrand J, Grais R, Boelle P, et al. Understanding the dynamics of Ebola epidemics. Epidemiol Infect 2007; 135: 610-621
24. WHO Ebola Response Team. Ebola virus disease in West Africa-the first 9 months of the epidemic and forward projections. N Engl J Med 2014; 371: 1481-1495
25. Rosenbaum PR., Interference between units in randomized experiments. J Am Stat Assoc 2007; 102: 191-200
26. Onnela J-P, Saramäki J, Hyvönen J, et al. Structure and tie strengths in mobile communication networks. Proc Natl Acad Sci USA 2007; 104: 7332-7336
27. Onnela J-P, Arbesman S, González MC, et al. Geographic constraints on social network groups. PLoS ONE 2011; 6: e16939
28. Wesolowski A, Eagle N, Tatem AJ, et al. Quantifying the impact of human mobility on malaria. Science 2012; 338: 267-270
29. Staples PC, Ogburn EL, Onnela JP., Incorporating contact network structure in cluster randomized trials. Sci Rep 2015; 5: 17581
30. Wesolowski A, Stresman G, Eagle N, et al. Quantifying travel behavior for infectious disease research: a comparison of data from surveys and mobile phones. Sci Rep 2014; 4: 5679
31. Tuite AR, Tien J, Eisenberg M, et al. Cholera epidemic in Haiti, 2010: using a transmission model to explain spatial spread of disease and identify optimal control interventions. Ann Intern Med 2011; 154: 593-601
32. Carnegie NB, Wang R, DeGruttola V,. Estimation of the overall treatment effect in the presence of interference in cluster-randomized trials of infectious disease prevention. Epidemiol Meth. Epub ahead of print 6 August 2016. DOI: 10.1515/em-2015-0016